Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

FHTX Foghorn Therapeutics Inc

Price (delayed)

$4.2

Market cap

$234.11M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.36

Enterprise value

$206.23M

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. The ...

Highlights
Foghorn Therapeutics's EPS has increased by 38% YoY and by 14% from the previous quarter
The company's debt fell by 19% YoY and by 6% QoQ
The equity has grown by 37% YoY but it has contracted by 35% from the previous quarter
The company's revenue fell by 31% YoY but it rose by 4% QoQ
FHTX's quick ratio is down by 22% year-on-year and by 15% since the previous quarter

Key stats

What are the main financial stats of FHTX
Market
Shares outstanding
55.74M
Market cap
$234.11M
Enterprise value
$206.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
11.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.77
Earnings
Revenue
$23.5M
Gross profit
$23.5M
Operating income
-$97.4M
Net income
-$80.44M
EBIT
-$80.44M
EBITDA
-$71.61M
Free cash flow
-$95.86M
Per share
EPS
-$1.36
EPS diluted
-$1.36
Free cash flow per share
-$1.53
Book value per share
-$1.11
Revenue per share
$0.37
TBVPS
$4.12
Balance sheet
Total assets
$258.69M
Total liabilities
$320.34M
Debt
$34.85M
Equity
-$61.65M
Working capital
$154.11M
Liquidity
Debt to equity
-0.57
Current ratio
3.16
Quick ratio
3.12
Net debt/EBITDA
0.39
Margins
EBITDA margin
-304.7%
Gross margin
100%
Net margin
-342.2%
Operating margin
-414.4%
Efficiency
Return on assets
-27.3%
Return on equity
N/A
Return on invested capital
-42%
Return on capital employed
-42.9%
Return on sales
-342.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FHTX stock price

How has the Foghorn Therapeutics stock price performed over time
Intraday
-3.67%
1 week
-2.33%
1 month
-0.94%
1 year
-26.06%
YTD
-11.02%
QTD
15.07%

Financial performance

How have Foghorn Therapeutics's revenue and profit performed over time
Revenue
$23.5M
Gross profit
$23.5M
Operating income
-$97.4M
Net income
-$80.44M
Gross margin
100%
Net margin
-342.2%
FHTX's operating margin is down by 37% YoY but it is up by 9% QoQ
The company's revenue fell by 31% YoY but it rose by 4% QoQ
FHTX's gross profit is down by 31% year-on-year but it is up by 4% since the previous quarter
The company's net margin fell by 25% YoY but it rose by 11% QoQ

Price vs fundamentals

How does FHTX's price correlate with its fundamentals

Growth

What is Foghorn Therapeutics's growth rate over time

Valuation

What is Foghorn Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
11.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.77
Foghorn Therapeutics's EPS has increased by 38% YoY and by 14% from the previous quarter
The equity has grown by 37% YoY but it has contracted by 35% from the previous quarter
FHTX's P/S is 94% lower than its 5-year quarterly average of 175.9 and 14% lower than its last 4 quarters average of 13.1
The company's revenue fell by 31% YoY but it rose by 4% QoQ

Efficiency

How efficient is Foghorn Therapeutics business performance
Foghorn Therapeutics's ROS has decreased by 30% YoY but it has increased by 11% from the previous quarter
The ROA has grown by 12% YoY and by 7% from the previous quarter
FHTX's return on invested capital is up by 6% since the previous quarter

Dividends

What is FHTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FHTX.

Financial health

How did Foghorn Therapeutics financials performed over time
Foghorn Therapeutics's total assets is 19% lower than its total liabilities
FHTX's quick ratio is down by 22% year-on-year and by 15% since the previous quarter
The current ratio has contracted by 22% YoY and by 15% from the previous quarter
The company's debt is 157% higher than its equity
The equity has grown by 37% YoY but it has contracted by 35% from the previous quarter
The debt to equity is up by 30% QoQ but it is down by 30% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.